Companies in #Degenerative Muscle Disease
Found 1 company operating in this sector.
Satellos Bioscience is a clinical-stage biotechnology company developing novel small-molecule therapies to treat degenerative muscle diseases, with lead candidate SAT-3247 in Phase 2 development for Duchenne muscular dystrophy. The company reported six-month interim data from the TRAILHEAD study in July 2026 showing reduced muscle-fat fraction and improved biomarker signals, and received FDA Fast Track designation for SAT-3247 in June 2026. Satellos is dual-listed on Nasdaq and the TSX and reported cash and equivalents of approximately Cdn $97.5 million as of Q1 2026 with cash runway through 2027.